• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tactile Systems Technology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/9/25 4:56:54 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care
    Get the next $TCMD alert in real time by email
    false 0001027838 TACTILE SYSTEMS TECHNOLOGY INC 0001027838 2025-05-07 2025-05-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):  May 7, 2025

     

    TACTILE SYSTEMS TECHNOLOGY, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37799   41-1801204
    (State or other jurisdiction of   (Commission   (IRS Employer
    incorporation)   File Number)   Identification No.)

     

    3701 Wayzata Blvd, Suite 300, Minneapolis, MN 55416

    (Address of principal executive offices) (Zip Code)

     

    (612) 355-5100

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which
    registered
    Common Stock, Par Value $0.001 Per Share TCMD The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  ¨ Emerging growth company

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

      

     

     

     

    Item 5.02.Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    As reported below in Item 5.07, on May 7, 2025, the stockholders of Tactile Systems Technology, Inc. (the “Company”) approved the Tactile Systems Technology, Inc. 2025 Equity Incentive Plan (the “2025 Plan”). The 2025 Plan was approved by the Company's Board of Directors (the "Board") on March 25, 2025, subject to stockholder approval, and became effective with such stockholder approval on May 7, 2025.

     

    The 2025 Plan provides for the issuance of up to 1,850,000 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”). Any shares of Common Stock subject to an award under the 2025 Plan, or to an award under the Company’s 2016 Equity Incentive Plan (the “2016 Plan”) that was outstanding on May 7, 2025, that expires, is forfeited or cancelled, is settled for cash or otherwise does not result in the issuance of all of the shares subject to such award will, to the extent of such cancellation, forfeiture, expiration, cash settlement or non-issuance, become available for future awards under the 2025 Plan. Following the stockholders' approval of the 2025 Plan, no further awards will be granted under the 2016 Plan.

     

    Awards under the 2025 Plan may be granted to employees, consultants and advisors of the Company, as well as to the non-employee directors of the Company. Awards under the 2025 Plan can be granted in the form of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards. The 2025 Plan will be administered by the Compensation and Organization Committee of the Company's Board.

     

    A description of the 2025 Plan was included in the Company’s proxy statement for its annual meeting of stockholders filed with the Securities and Exchange Commission on March 28, 2025. A copy of the 2025 Plan, the Form of Restricted Stock Unit Award Agreement (Executives) for use under the 2025 Plan, the Form of Restricted Stock Unit Award Agreement (Non-Employee Directors) for use under the 2025 Plan and the Form of Performance Stock Unit Agreement for use under the 2025 Plan are filed as Exhibit 10.1, 10.2, 10.3 and 10.4, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

     

    Item 5.07.Submission of Matters to a Vote of Security Holders

     

    On May 7, 2025, the Company held its 2025 Annual Meeting of Stockholders and the Company’s stockholders voted on the following matters:

     

    Election of Directors

     

    The following nominees were elected to serve as directors for a term that will last until the Company’s 2026 Annual Meeting of Stockholders or until his or her successor is duly elected and qualified. The number of votes cast for and withheld from each nominee and the number of broker non-votes with respect to each nominee were as follows:

     

    Name  Votes For   Votes Withheld   Broker Non-Votes 
    William W. Burke   15,557,077    436,231    3,037,240 
    Valerie L. Asbury   15,267,124    726,184    3,037,240 
    Sheri L. Dodd   15,796,147    197,161    3,037,240 
    Raymond O. Huggenberger   15,756,282    237,026    3,037,240 
    Laura G. King   15,862,873    130,435    3,037,240 
    D. Brent Shafer   14,929,921    1,063,387    3,037,240 
    Carmen B. Volkart   15,796,104    197,204    3,037,240 
    B. Vindell Washington   15,774,288    219,020    3,037,240 

     

     

     

     

    Ratification of the Selection of Grant Thornton LLP as the Company’s Independent Auditor for 2025

     

    The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025 by voting as follows:

     

    For  Against   Abstain   Broker Non-Votes 
    18,900,463   121,340    8,745    0 

     

    Advisory Vote on Approval of the Compensation of the Company’s Named Executive Officers

     

    The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers by voting as follows:

     

    For  Against   Abstain   Broker Non-Votes 
    15,658,844   321,637    12,827    3,037,240 

     

    Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of the Company’s Named Executive Officers

     

    The Company’s stockholders voted as follows on the frequency of future advisory votes on the compensation of the Company’s named executive officers:

     

    1 Year  2 Years   3 Years   Abstain   Broker Non-Votes 
    14,948,653   7,171    1,020,661    16,823    3,037,240 

     

    Based on these results, and consistent with the Board’s recommendation, the Board has determined that the Company will hold future advisory votes to approve the compensation of the Company’s named executive officers every year, until the next required vote on the frequency of future advisory votes on executive compensation.

     

    Approval of the Company’s 2025 Equity Incentive Plan

     

    The Company’s stockholders approved the Company’s 2025 Equity Incentive Plan by voting as follows:

     

    For  Against   Abstain   Broker Non-Votes 
    15,286,584   697,589    9,135    3,037,240 

     

    Item 9.01.Financial Statements and Exhibits

     

    (d) Exhibits

     

    EXHIBIT INDEX

     

    Exhibit
    No.
      Description
         
    10.1   Tactile Systems Technology, Inc. 2025 Equity Incentive Plan.
    10.2   Form of Restricted Stock Unit Award Agreement (Executives) under the 2025 Equity Incentive Plan.
    10.3   Form of Restricted Stock Unit Award Agreement (Non-Employee Directors) under the 2025 Equity Incentive Plan.
    10.4   Form of Performance Stock Unit Agreement under the 2025 Equity Incentive Plan.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

      TACTILE SYSTEMS TECHNOLOGY, INC.
       
    Date: May 9, 2025 By: /s/ Elaine M. Birkemeyer
        Elaine M. Birkemeyer 
        Chief Financial Officer

     

     

     

    Get the next $TCMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TCMD

    DatePrice TargetRatingAnalyst
    5/6/2025$14.00Overweight → Neutral
    Piper Sandler
    2/19/2025$23.00 → $18.00Buy → Neutral
    B. Riley Securities
    11/5/2024Outperform → Perform
    Oppenheimer
    11/5/2024Buy → Neutral
    BTIG Research
    9/26/2024$23.00Buy
    B. Riley Securities
    More analyst ratings

    $TCMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tactile Systems downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Tactile Systems from Overweight to Neutral and set a new price target of $14.00

    5/6/25 8:04:03 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Systems downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Tactile Systems from Buy to Neutral and set a new price target of $18.00 from $23.00 previously

    2/19/25 7:05:55 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Systems downgraded by Oppenheimer

    Oppenheimer downgraded Tactile Systems from Outperform to Perform

    11/5/24 7:15:44 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Tactile Systems Technology Inc.

    SCHEDULE 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    8/7/25 11:54:51 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Tactile Systems Technology Inc.

    10-Q - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

    8/4/25 4:07:09 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Systems Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)

    8/4/25 4:05:14 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Dodd Sheri Louise sold $95,907 worth of shares (7,762 units at $12.36), decreasing direct ownership by 4% to 173,479 units (SEC Form 4)

    4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

    8/12/25 6:03:32 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Birkemeyer Elaine M. sold $29,037 worth of shares (2,921 units at $9.94), decreasing direct ownership by 3% to 99,111 units (SEC Form 4)

    4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

    5/14/25 5:26:59 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Dodd Sheri Louise sold $30,955 worth of shares (3,149 units at $9.83), decreasing direct ownership by 2% to 181,241 units (SEC Form 4)

    4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)

    5/12/25 4:34:53 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tactile Systems Technology, Inc. Reports Second Quarter 2025 Financial Results

    MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 7.8% year-over-year to $78.9 millionGross margin of 75% versus 74% in Q2 2024Net income of $3.2 million versus $4.3 million in Q2 2024Adjusted EBITDA of $7.7 million versus $9.1 million in Q2 2024Announced the presentation of new data demonstrating significant benefits associated with use of Flexitouch Plus in treatin

    8/4/25 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Medical to Release Second Quarter of Fiscal Year 2025 Financial Results on August 4, 2025

    MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2025 financial results will be released after the market closes on Monday, August 4, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 4, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13754589. A live webcast of the call will also be provided o

    7/21/25 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    New Data Demonstrates Significant Clinical and Quality-of-Life Benefits of Flexitouch® Plus in Treating Lymphedema Among Head and Neck Cancer Survivors

    MINNEAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the presentation of new clinical data at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting that demonstrates significant clinical and quality-of-life benefits associated with use of the Company's Flexitouch Plus versus usual care in treating patients with head and neck cancer-related lymphedema. "Current modalities for managing head and neck cancer-related lymphedema include therapist guided lymphedema treatment and lifelong home-based self-car

    6/3/25 8:00:00 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    Leadership Updates

    Live Leadership Updates

    View All

    Tactile Medical Appoints Laura King to Board of Directors

    MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company's Board of Directors ("Board") and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE

    1/13/25 8:00:00 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    LifeLens Technologies Expands Executive Leadership Team and Board of Directors

    PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors: Daniel J. Sullivan, Chairman of the Board of LifeLens, as Chief Executive OfficerBrent A. Moen as Chief Financial OfficerRichard J. Buchholz as a member of the Board of Directors "With LifeLens, we have a significant opportunity to disrupt healthcare and make a meaningful impact on patients and healthcare professionals, and we are thrilled to have Brent and Rick join the LifeLens tea

    11/8/23 7:30:00 AM ET
    $INSP
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Medical Appoints Vindell Washington, M.D. to Board of Directors

    MINNEAPOLIS, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Vindell Washington, M.D. to the Company's Board of Directors ("Board"), effective October 2, 2023. "We are pleased to welcome Dr. Washington to Tactile Medical, who joins our Board with over 30 years of experience in the healthcare industry," said Bill Burke, Chairman of the Board of Tactile Medical. "We will benefit from his breadth of experience in medicine, technology and policy, as well as his expertise in advising healthcare companies on their clinical s

    10/2/23 4:05:00 AM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    Financials

    Live finance-specific insights

    View All

    Tactile Systems Technology, Inc. Reports Second Quarter 2025 Financial Results

    MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 7.8% year-over-year to $78.9 millionGross margin of 75% versus 74% in Q2 2024Net income of $3.2 million versus $4.3 million in Q2 2024Adjusted EBITDA of $7.7 million versus $9.1 million in Q2 2024Announced the presentation of new data demonstrating significant benefits associated with use of Flexitouch Plus in treatin

    8/4/25 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Medical to Release Second Quarter of Fiscal Year 2025 Financial Results on August 4, 2025

    MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2025 financial results will be released after the market closes on Monday, August 4, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 4, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13754589. A live webcast of the call will also be provided o

    7/21/25 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results

    MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1 2024Adjusted EBITDA loss of $0.3 million versus positive Adjusted EBITDA of $1.0 million in Q1 2024Repurchased $10.0 million of stock under the Company's share repurchase programExpanded launch of

    5/5/25 4:05:00 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    $TCMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tactile Systems Technology Inc.

    SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 7:29:11 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/13/24 5:04:27 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tactile Systems Technology Inc.

    SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

    11/8/24 3:21:42 PM ET
    $TCMD
    Medical/Dental Instruments
    Health Care